Studies have shown that PI3K/AKT phosphorylation inhibits Bax activity and promotes the release of Bcl-2 [53,54], which confirms the potential therapeutic effect of this bacterium as an anti-cancer drug (Figure 4). The gene discussed is AKT1; the disease is cancer.